Redenlab supporting PTC Theraputics in Global Phase 3 Clinical Trial

Redenlab are proud to be supporting PTC Therapeutics, Inc. Global Phase 3 Clinical Trial to Evaluate Vatiquinone in Friedreich #Ataxia.

The Phase 3 MOVE-FA trial is an 18-month parallel arm, placebo-controlled study evaluating vatiquinone versus placebo in approximately 110 children and young adults with FA. The primary endpoint is the change from baseline in the modified Friedreich ataxia rating scale (mFARS), with key secondary endpoints assessing ambulation and activities of daily living (incl #speech). This endpoint strategy was developed in consultation with both the FDA and European Medicines Agency. The study will include sites in the U.S., E.U., Australia and Latin America.

Click here for more details.

Related Post

  • Posted on 24 October, 2023
    Speech disorders impacting children have debilitating impacts on educational, social and later employment outcomes. There are limited therapeutic options for...
    • Posted on 24 October, 2023
      Spinocerebellar ataxia Type 1 (SCA1) is a dominantly inherited neurodegenerative disease resulting in balance, speech, thinking and coordination difficulties. SCA1...
      • Posted on 24 October, 2023
        Friedreich ataxia (FA) is a progressive, genetically inherited multisystem disease that affects children and adults. FA leads to significant changes...